CLOs on the Move


 
Armune BioScience, Inc. develops and commercializes molecular diagnostic and prognostic tests for prostate, lung, and breast cancers that will allow physicians and patients to make more personalized treatment decisions. The company was founded by members of the Apjohn Group, LLC, a business accelerator that brings together valuable resources of management talent and angel/seed financing. The company’s corporate headquarters are in Kalamazoo, MI and the laboratory is in Ann Arbor, MI.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.armune.com
  • 350 E Michigan Ave Suite 500
    Kalamazoo, MI USA 49007
  • Phone: 269.349.8870

Executives

Name Title Contact Details

Similar Companies

OncoImmune

Based in Rockville, Maryland, OncoImmune is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biopharmaceuticals for the treatment of cancer and autoimmune disease.

New Century Pharmaceuticals

New Century Pharmaceuticals is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Capital Technology Information Services

Capital Technology Information Services is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nova Biologics.

Nova Biologics. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nexstim

Founded in Finland in 2000, Nexstim is the world leader in Navigated Brain Stimulation (NBS) with image-guided Transcranial Magnetic Stimulation (TMS). The company is committed to improving the quality of life of patients. Nexstim has pioneered the technology for brain diagnostics with the Navigated Brain Stimulation (NBS) System as the first and only FDA-cleared and CE-marked navigated TMS (nTMS) device for pre-surgical mapping of the motor and speech cortices. The advanced technology providing navigation to TMS has led NBS to be recognized as the emerging standard for pre-operative direct functional mapping. Nexstim initiated its two year multicenter clinical trial on the therapeutic effects of nTMS for stroke rehabilitation in June 2014 with Navigated Brain Therapy